Thomas Jefferson University

Jefferson Digital Commons
Department of Medicine Faculty Papers

Department of Medicine

11-1-2021

Diabetes in Kidney Transplantation.
Maria P Martinez Cantarin

Follow this and additional works at: https://jdc.jefferson.edu/medfp

Let us know how access to this document benefits you
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Department of Medicine Faculty Papers by an authorized administrator of the Jefferson
Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Diabetes in kidney transplantation
Maria P Martinez Cantarin, MD
833 Chestnut Street Suite 700, Philadelphia, PA, 19147. Phone 215-955-6550, Fax 215-503-4099
maria.p.martinezcantarin@jefferson.edu
Sidney Kimmel Medical College at Thomas Jefferson University
Department of Medicine, Division of Nephrology
The author reports no conflict of interest.
Short title: Diabetes and transplant

1

1. Abstract
Diabetes mellitus (DM) is one of the most common complications after kidney transplantation
and is associated with unfavorable outcomes including death. DM can be present before
transplant but post-transplant diabetes mellitus (PTDM) refers to diabetes that is diagnosed
following solid organ transplantation. Despite its high prevalence, optimal treatment to prevent
complications of PTDM are unknown. Medical therapy of pre-existent DM or PTDM after
transplant

is

challenging

due

to

frequent

interactions

between

antidiabetic

and

immunosuppressive agents. There is also frequent need for medication dose adjustments due to
residual kidney disease and a higher risk of medication side effects in patients treated with
immunosuppressive agents. Sodium glucose 2 inhibitors (SGLT2-i) have demonstrated a favorable
cardio-renal profile in patients with DM without a transplant and hence hold great promise in this
patient population although there is concern about the higher risk of urinary tract infections. The
significant gaps in our understanding of the pathophysiology, diagnosis and management of
diabetes mellitus after kidney transplantation need to be urgently addressed.

2. Clinical summary
a. Diabetes mellitus after transplant, which includes pre-existing diabetes and posttransplant diabetes, is extremely common and is associated with increased morbidity and
mortality.
b. The pathogenesis of post-transplant diabetes shares similarities with other subgroups of
type 2 diabetes. However, PTDM presents distinct drivers for metabolic dysfunction
including calcineurin inhibitor toxicity to the pancreatic beta cell, thus making PTDM a
separate entity.
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c. Fasting glucose and hemoglobin A1c may not reflect the altered metabolism after an
organ transplant making the diagnosis of PTDM more challenging. Oral glucose tolerance
test should be considered the gold standard for its diagnosis.
d. Optimal treatments goals in PTDM are unknown.
e. SGLT2-i have demonstrated efficacy and safety in the treatment of non-transplant related
DM with improvement in cardiovascular risk and decrease in kidney disease progression.
However, SGLT2-i therapy post-kidney transplant may pose a substantially higher risk of
genitourinary infections and vasomotor acute kidney injury. Studies to determine
whether SGLT2-i provide clinical benefits including cardiovascular prevention and
nephroprotective effects are need post-transplant.

3. Introduction
DM is a common complication of kidney transplantation. In the US, almost 50% of the incident end stage
kidney disease patients have DM and diabetes is the primary cause of kidney disease in 22% of kidney
transplant recipients1. Furthermore, 2 to 50% of patients that did not have DM before kidney transplant,
will develop it post-transplant2. DM in a kidney transplant recipient is associated with significant morbidity
and mortality independently of whether it was present pre-transplant. Diabetic kidney transplant
recipients have reduced overall survival3 with increased cardiovascular complications and infections.
Despite its high prevalence and association with poor outcomes, optimal management strategies for DM
after kidney transplant are unknown. Interactions between immunosuppressive medications and antidiabetic agents make its treatment challenging. The persistence of chronic kidney disease (CKD), high
frequency of episodes of acute kidney injury (AKI) and worsening kidney function also complicates
therapy.
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The current review will focus on the burden of type 2 diabetes (T2DM) after transplant with a brief
discussion on the treatment of type 1 diabetes (T1DM). We will review the epidemiology and pathogenesis
of PTDM, the diagnostic challenges, risk factors and outcomes as well as management strategies.
4. Post-transplant diabetes mellitus
a. Definition
PTDM refers to diabetes mellitus that is diagnosed after kidney transplant, and acknowledges that some
patients may have had undiagnosed pre-transplant DM. This is in contrast to the old nomenclature of new
onset diabetes after transplant (NODAT) that assumed that the patients did not have DM prior to
transplant. Currently, it is estimated that up to 10% of patients with the diagnosis of PTDM have
undiagnosed diabetes pre-kidney transplantation4.
b. Incidence.
The scientific literature reports wide variations in the prevalence of DM after transplant, which is partly
due to a lack of historic consistent criteria for its diagnosis. In 2003 consensus guidelines were published
to aid in the diagnosis of diabetes mellitus after transplant5 and more contemporary series using the
guideline’s criteria reflect a PTDM prevalence of 10-30%6,7. The incidence of PTDM is higher in non-kidney
organ transplant recipients. Incidence of PTDM in heart transplant recipients ranges between 20-30%, in
liver transplant recipients 20-40% and lung transplant recipients 20-40%8.
c. Diagnosis
The diagnosis of PTDM relies on the same criteria that are used to diagnose DM in the non-transplant
population9. In brief, diabetes mellitus after kidney transplant is diagnosed if fasting glucose ≥ 126 mg/dL
(7 mmol/L) on more than one occasion, random glucose ≥ 200 mg/dL (11.1 mmol/L) with symptoms, or a
2-hour glucose level after a 75-g oral glucose tolerance test (OGTT) ≥ 200 mg/dL (11.1 mmol/L). OGTT is
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more sensitive than fasting glucose alone and should be considered the gold standard for the early
diagnosis of PTDM since PTDM presents often with postprandial hyperglycemia and normal fasting
glucose levels10,11. In 2013 a panel of transplant nephrologists, surgeons, diabetologists, and clinical
scientists reviewed and updated the criteria for PTDM. The review clarified issues specific to transplant
recipients12 such as the use of hemoglobin A1c (HbA1c) and proposed standard PTDM nomenclature.
Some key points from the consensus conference will be highlighted here.
Short term hyperglycemia is common in the immediate post-transplant period and is attributable in part
to different post-surgical stressors such as inflammation, use of high dose steroids for the induction of
immunosuppression, infections and a high frequency of enteral or parenteral nutrition13,14. As a result, in
order to ensure a uniform and consistent diagnosis of PTDM, it was proposed that the diagnosis should
be made when allograft function and immunosuppression levels are stable, and other perioperative
complications (e.g. infection and/or rejection) are resolved.
OGTT should remain the gold standard for the diagnosis of PTDM as it is more sensitive than relying
exclusively on fasting glucose levels 10,11. OGTT also screens for impaired glucose tolerance (IGT) which is
not only a risk factor for development of PTDM but is also an independent risk factor for cardiovascular
disease and mortality 15,16. Despite its value, OGTT is not used widely in clinical practice due to need for
more resources.
HbA1c levels in the early post-transplant period are unreliable, especially if low. After transplant,
erythropoiesis is reduced with immunosuppressive medications and the persistence of kidney disease
driving anemia. Treatment of anemia often requires erythropoietin analogs which will alter red blood cell
survival. Post-transplant transfusions may also influence HbA1C levels. Due to changes in red cell turnover,
hemoglobin concentration, and even glucose concentration in the early post-transplant period, a normal
HbA1c does not exclude PTDM17. On the other hand, glycosylated hemoglobin levels between 5.7 and
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6.4% in the early post-transplant period or with anemia, may reflect the need to perform an OGTT since
it is the best diagnostic tool and should alert us to the possibility of PTDM.
After the 2013 consensus meeting, most subsequent transplant guidelines advocate screening for PTDM
with fasting blood sampling and HbA1c to determine the patients at risk who will benefit from an OGTT.
d. Risk factors
Risk factors for the development of PTDM are similar to those that increase the risk prior to
transplantation, however, transplant specific risks also contribute (Table 1). The use of
immunosuppressive medications including calcineurin inhibitors (CNIs), steroids and mammalian target
of rapamycin (mTOR) inhibitors, infections such as hepatitis C, and hypomagnesemia are specific factors
associated with increased risk of PTDM. CNIs, which include tacrolimus (Tac) and cyclosporine (CSA), are
the cornerstone of immunosuppressive therapy, and are more commonly used than mTOR inhibitors such
as sirolimus or everolimus. CNIs promote PTDM by inhibiting crucial signaling pathways for pancreatic βcell growth and function18. The diabetogenic potential of CNIs is dose dependent19 and Tac is considered
more diabetogenic than CSA20. mTOR inhibitors are also associated with development of PTDM at higher
rates than CSA but at lower rates than Tac21. Weight gain, which induces insulin resistance, is another
factor that is more prevalent in post-transplant patients.

Significant weight gain after kidney

transplantation is common, as a consequence of the use of steroids and the dissipation of uremic
anorexia. Counseling on appropriate weight management and healthy habits should be part of the posttransplant counseling and avoidance of weight gain may reduce risk of PTDM.
e. Pathogenesis
PTDM shares multiple pathophysiological characteristics with pre-transplant DM but, since PTDM has
distinct mechanisms that eventually lead to hyperglycemia, is now considered a separate entity. As in pretransplant DM, PTDM presents dysfunctional insulin sensitivity (IS)22,23, abnormal insulin production with
6

pancreatic β-cell dysfunction24,25, lack of glucagon suppression with hyperglycemia26, as well as
hypertriglyceridemia, obesity, and low-grade inflammation27,28. The dominant mechanism that leads to
the development of PTDM is still an area of debate although several groups propose that β-cell
dysfunction is the main pathophysiological process10,11,24,25. The role of insulin resistance in the
development of PTDM is less clear as timing and methods used for evaluation of insulin sensitivity vary
widely between studies 29. One way to explain the post-transplant differences observed could be the fact
that insulin sensitivity is a dynamic process that changes significantly over time. This possibility was
examined by Hjelmesaethh et al.30,31 who studied insulin sensitivity by OGTT and insulin measurements at
10 weeks, 1 year, and 6 years post renal transplantation. Early post-transplant patients had decreased
insulin sensitivity and defects in insulin secretion. The magnitude of the defect on insulin sensitivity and
secretion correlated with the glucose tolerance state and development of PTDM. Between 1- and 6-years
post-transplant, patients with PTDM continue to have significant reduction of insulin secretion but no
longer show significant differences in insulin sensitivity compared to patients with normal glucose
tolerance. Data from these studies may reflect the fact that defects in insulin secretion after transplant
are more constant, most likely due to the persistent use of β-cell toxic immunosuppression whereas
insulin sensitivity can vary more widely. More recently, alterations in the incretin axis between the gut
and pancreas have also been demonstrated in patients with PTDM. Patients with DM have a defect in the
incretin system with decreased insulin and increased glucagon release in response to a glucose load that
improves with glucagon-like peptide 1 (GLP1) agonist treatment. Patients with PTDM, like those with DM
unrelated to transplantation, have reduced glucose-induced insulin secretion and attenuated glucagon
suppression when studied with the hyperglycemic clamp, the gold standard test to assess insulin secretion
capacity and beta cell response to glucose. In this study, GLP1 infusion also improved insulin and glucagon
responses to hyperglycemia in patients with PTDM26.
f.

Outcomes/Complications
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DM pre- or post-transplant is associated with increased morbidity and mortality. Similarly to T2DM,
development of PTDM is associated with a significant increase in cardiovascular disease32-34 risk and
death7,14,35. Specifically, PTDM is associated with a 60% increase in post-transplantation myocardial
infarction36, increased risk of cerebrovascular accidents33, as well as aortic or lower extremity arterial
disease33,34. Interestingly, despite the higher mortality risk, graft viability is not impacted by PTDM since
death censored graft loss does not differ16. Besides the increased risk of macrovascular disease and death
with development of PTDM, these patients may also develop microvascular disease related complications
at an accelerated rate37. The risk of increased morbidity and mortality with PTDM has also been
demonstrated in pre-diabetic states including impaired glucose tolerance and impaired fasting
glucose15,38. To summarize, PTDM and its precursor states are associated with poor outcomes including a
higher risk of microvascular and macrovascular disease although graft survival is not affected.
5. Management of diabetes mellitus after transplant
Management strategies for treatment of PTDM should aim to improve β- cell function and decrease
insulin resistance.
In contrast with T2DM, there are no specific glucose or A1c targets for the treatment of PTDM as there is
no data on the degree of glycemic control that is associated with reduction of complications after
development of PTDM39. Despite this, most transplant centers will aim for HbA1c of 7-7.5% as suggested
in the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines for the management of transplant
recipients40. Due to the possibility that diabetic complications occur early after transplant37 and lead to
poor outcomes, we advocate treating PTDM aggressively and promptly after diagnosis making every effort
to avoid hypoglycemia. On the other hand, it is reasonable to consider higher thresholds for older and
debilitated patients.
a. Lifestyle changes and bariatric surgery.
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Lifestyle modifications should be emphasized as one of the initial treatments of PTDM since a combination
of exercise and weight loss improves insulin sensitivity and β-cell function in diabetic patients41,42 although
its effectiveness in PTDM is limited to a few small studies. A combined approach to diet and weight loss
have shown complete reversal of impaired glucose tolerance after 6 months post-transplant in a nonrandomized study43 whereas a randomized control trial of active versus passive lifestyle interventions was
only able to show improvement in weight loss and reduction of fat mass without improvement in glucose
metabolism44. Unfortunately, more data are needed to determine the real effect of lifestyle modifications
to prevent development of PTDM. The role of bariatric surgery before or after kidney transplantation to
decrease the risk of PTDM is also underexplored, with just a few reports citing the experience of individual
centers in a small number of patients45-47. Due to the evolution and improvement of bariatric surgery
techniques, excellent outcomes and safety profile in the general non – transplant population and growing
data from the transplant population48, bariatric surgery could be considered for a select population
depending on the risk factor profile and expected time to transplantation.
b. Antidiabetic medications
A recent review by Cohen et al.49 summarizes therapeutic studies in the context of PTDM and highlights
the paucity of available data. Older drugs such as the biguanide metformin, secretagogues such as glipizide
and repaglinide as well as thiazolidinediones have been used for the treatment of PTDM and have
demonstrated safety, low drug to drug interactions with immunosuppressive medications and efficacy in
lowering blood glucose. It is important to remember that CNIs are metabolized via cytochrome p450 3A4
(CYP3A4) so drugs that interact with the CYP3A4 pathway can significantly alter CNIs drug levels. At the
time of starting antidiabetic treatment several issues should be considered: a) drug to drug interactions,
b) exacerbation of the side effects of immunosuppressant medications when used concomitantly with
oral antidiabetic therapies with similar side effects, and c) kidney clearance of the different drugs as
transplant patients will have different degrees of residual kidney disease.
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i.

Post-surgical period

Insulin is the main antidiabetic medication used in the immediate post-transplant period. Data from a
small proof of concept study showed that patients with blood glucose >140 mg/dL treated with insulin
early post-transplantation had decreased risk of PTDM compared to patients treated with oral antidiabetic
agents. The study proposed early insulin therapy to protect β-cell function toxicity from hyperglycemia
and decrease PTDM incidence14. A large randomized control trial, the ITP-NODAT trial (Early postoperative
basal insulin therapy for the prevention of post-transplant diabetes onset after kidney transplantation),
also corroborates the findings of the small non randomized study50.
Dipeptidyl peptidase 4 (DPP-4) inhibitors have been shown to improve insulin sensitivity as well as β-cell
function51. Vidagliptin, a DPP-4 inhibitor, has been shown to be safe and efficacious in kidney transplant
patients52 and a randomized trial is underway to test if vidagliptin could prevent PTDM development when
used immediately post-transplant compared to placebo53.
ii.

Metformin

Metformin is still considered the first line therapy for DM treatment, but the association of metformin
with lactic acidosis specifically in the setting of worsening kidney function complicates its use in posttransplant patients. Despite the risk of lactic acidosis, metformin can still be prescribed to patients with
moderately reduced kidney function (glomerular filtration rate or GFR 30-59 mL/min)54. Metformin has
minimal drug-drug interactions with immunosuppressant medications, but potentiation of metformin
gastrointestinal (GI) side effects is possible when used concomitantly with mycophenolate mofetil (MMF).
Close monitoring of kidney function is advisable during metformin therapy, in order to avoid potential
treatment-related complications. In a small randomized trial that used metformin in patients that
developed IGT 4-12 weeks post-transplant, metformin was well tolerated but did not show differences in
metabolic profile compared to untreated patients55. Recent guidelines by the Association of British Clinical
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Diabetologists (ABCD) and by the British Renal Association (RA) on the Detection and Management of
Diabetes post-Solid Organ Transplantation continue to recommend metformin use if GFR allows it as one
of the first line therapies in PTDM56. Further studies are needed to determine the efficacy of metformin
in the prevention and management of PTDM.
iii.

Sulfonylureas and glinides

Sulfonylureas and glinides stimulate pancreatic secretion of insulin independently of glucose levels. In
contrast to glinides, most of the sulfonylureas significantly accumulate with kidney disease increasing the
risk of hypoglycemia. Glinides are safer drugs in patients with kidney disease and more widely used posttransplantation. Unfortunately, despite frequent clinical utilization, there are only a few small studies that
have tested these drugs in the setting of PTDM57,58.
iv.

Glucagon-like peptide 1 receptor agonists (GLP1‐RAs)

GLP1-RAs improve glycemic control in T2DM through enhanced glucose-dependent insulin secretion,
inhibition of glucagon release, delayed gastric emptying, appetite suppression, and inhibition of β-cell
apoptosis59. Liraglutide, semaglutide and dulaglutide do not have significant kidney clearance, making
them attractive agents in kidney transplant recipients. There is minimal data on liraglutide and dulaglutide
safety after kidney transplantation60-62. In theory, GLP1-RAs may potentially exacerbate the frequent GI
side effects seen with MMF due to their effect in delaying gastric emptying although this has not been
observed in studies using dulaglutide.
v.

Dipeptidyl peptidase 4 (DPP-4) inhibitors

DPP-4 inhibitors inactivate DPP4, the enzyme responsible for inactivation of glucose-dependent
insulinotropic polypeptide (GIP) and GLP-1, thus enhancing glucose control. In contrast to GLP1-RAs, DPP4 inhibitors have significant kidney clearance and dose reduction is necessary in patients with CKD.
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Linagliptin is the only DPP-4 inhibitor that is non-renally cleared with predominant biliary clearance. DPP4 inhibitors have some interactions with CNI metabolism as sitagliptin increases CSA levels and vidagliptin
can decrease Tac trough levels. Linagliptin, sitagliptin and vidagliptin have been used in kidney transplant
recipients with some benefits 52,63,64 and currently vidagliptin is being studied in a randomized controlled
study for its use in the early post-operative period53.
vi.

Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2-i)

The two newest additions to the DM therapy armamentarium have been SGLT2-i and GLP1‐RAs. SGLT2-i
have received more attention recently as their use in diabetic patients is associated with lower
cardiovascular disease risk and progression of CKD65-69. SGLT2-i selectively inhibit the sodium glucose cotransporter in the proximal convoluted tubule preventing glucose reabsorption. This mechanism of action
results in a loss of significant amounts of glucose in the urine. Increased glycosuria facilitates urinary water
losses which results in decreased blood pressure and weight loss, but also increases the risk of urinary
tract infections and ketoacidosis.
SGLT2-i have shown evidence of reducing kidney disease progression in patients with T2DM70-72 but trials
in the PTDM population have been scarce. These benefits are independent of glucose control as the mean
changes of HgA1c reported in clinical trials has been modest (around 0.5-0.6%)66,67. Recent published
reviews of trials involving use of SGLT2-i in transplant recipients advocate for their widespread use73,74
despite paucity of data. Currently, only a few observational and retrospective studies with SGLT2-i in a
small number of transplant recipients75-78 have been published and their main characteristics have been
summarized in Table 2. Similarly to the diabetic trials in the non-transplant population, the efficacy of
SGLT2-i in diabetic control is quite modest when used in patients with PTDM so most guidelines propose
its use as an add on therapy75-77,80,82
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Despite positive reviews, the main barrier to its widespread use in the transplant population has been the
increased risk of bacterial and fungal infections of the genitourinary tract and perineum, including
Fournier’s gangrene, increased risk of amputations, and euglycemic acidosis. The increased risk of
infections is thought to be related to the increased glucose content in the urine that makes a more
favorable environment for bacterial growth. Transplant patients are inherently at higher risk for urinary
tract and perineal infections due to immunosuppression and the physiological/anatomical changes that
occur in the post-transplant genitourinary tract. Current trials that used SGLT2-i in transplant recipients
have not demonstrated a higher risk of infection but data are limited due to small patient numbers. Other
risks associated with SGLT2-i use include hemodynamic AKI due to afferent arteriole vasoconstriction
coupled with volume loss due to its diuretic effect. None of these side effects have been reported in the
trials that involved kidney transplant recipients, but most of the trials that used SGLT2-i post-transplant
excluded patients with recurrent UTIs and patients within the first post-transplant year to minimize
toxicity risk.
In summary, despite its modest anti-glycemic effects, SGLT2-i may confer similar cardiovascular and renal
protection in kidney transplant recipients although further randomized control trials are needed to
confirm this. SGLT2-i should be combined with other anti-diabetic agents but due to its potential for
significant side effects, it seems prudent to limit its use to patients without a history of recurrent UTIs or
perineal infections and avoid its use during the first post-transplant year. Caution should be used when
given concomitantly with diuretics and antihypertensive medications due to potential changes in volume
status. Consider holding SGLT2-i during acute illness to minimize the risk of diabetic ketoacidosis and
vasomotor AKI.
c. Modification of immunosuppression
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Immunosuppression is one of the most important modifiable risk factors for PTDM. Tailoring
immunosuppression to patient risk for PTDM development is a logical step. Despite this, changes in
immunosuppression agents during the first post-transplant year carries the risk of promoting rejection. It
is well known that calcineurin inhibitors decrease insulin release from pancreatic β- cells and the use of
Tac is associated with higher risk of PTDM compared to CSA20. Conversion from Tac based to CSA based
immunosuppression in patients with PTDM was able to reverse diabetes mellitus in a significant number
of patients83. Also, since the risk of PTDM is dose dependent, other studies have demonstrated a benefit
on β-cell function with increased insulin secretion capacity once average Tac trough levels were decreased
from 9.5 to 6.4 ng/mL84. The use of mTOR inhibitors is also associated with the development of PTDM21
probably with lower risk than Tac but higher than CSA85. Some of the new immunosuppressant agents
such as Belatacept have demonstrated metabolic benefits with higher insulin release and lower risk of
PTDM development compared to Tac use86 and this may be an interesting option that should be rigorously
explored in clinical trials in subjects at high risk for PTDM. Antimetabolite use has not been demonstrated
to increase PTDM risk. Despite the well-known role of steroids in the development of hyperglycemia and
diabetes, the effect of steroids on the incidence of PTDM remains controversial. Several studies have
shown that the risk of developing diabetes mellitus post-transplant is similar in patients that are
maintained on steroids, versus patients that were not exposed to steroids or only exposed to steroids for
a limited period of time87-90. On the other hand, rapid steroid withdrawal in a study from Germany showed
significant reduction in the development of PTDM91. Transplant patients on 5 mg of prednisone
demonstrated similar insulin sensitivity to patients not on steroid therapy92. Unfortunately, there is no
data suggesting a benefit of immunosuppression adjustments without risk for increased rejection to
prevent the development of PTDM and caution should be used when changes are made with the sole
purpose of preventing diabetes.
d. Insulin pump treatment versus pancreas transplant for T1DM.
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Intensive insulin therapy either with intermittent subcutaneous injections or by continuous subcutaneous
delivery systems remains the cornerstone of therapy for patients with T1DM. Intensive insulin therapy
has been demonstrated to decrease microvascular disease progression in patients with T1DM but, despite
this, only a small proportion of patients meet the HgA1c goal set by the American Diabetes Association
(ADA) in the T1D Registry93,94 and most likely an even smaller proportion of the general population93. The
main barrier to achieve glucose control has been the risk of hypoglycemia. The technological
advancements in insulin pumps, continuous glucose monitoring systems (CGMs) and artificial pancreas,
where the capabilities of insulin pumps and CGMs are combined, have facilitated lower mortality,
increased quality of life and decreased incidence of hypoglycemia93,95,96. Despite these new technologies,
there are still multiple barriers to optimal glycemic control mainly related to their high cost and challenges
in deployment for populations with disabilities. Pancreas transplantation provides the most durable
replacement of β-cells in patients with insulin dependent diabetes. It is the most suitable therapy
particularly in patients with advanced CKD as pancreas transplantation could be carried out concomitantly
or after kidney transplantation. With a kidney transplant, the risk of long-standing immunosuppressive
therapy is already accepted so there is less concern about the negative effects of immunosuppression.
Pancreas transplantation not only improves quality of life but also has been demonstrated to decrease
microvascular end organ damage97. With improvements in long term outcomes and decreased morbidity
using current surgical techniques, pancreas transplantation is now available to a subset of insulin
dependent98 T2DM patients. In this subset, outcomes were excellent, with close to 90% of the patients
being free of diabetes 5 years post-transplant. Pancreas transplantation without a kidney is mainly
recommended for patients with T1DM with significant hypoglycemic unawareness despite CGMs or who
are unable to achieve benefits of advance monitoring technologies. Patients should be free of CKD and
proteinuria, as long-term use of immunosuppression will increase the risk of progressive kidney failure
due to the nephrotoxicity of CNIs. Islet allotransplantation, where islet cells isolated from a donor are
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injected into the portal vein of the recipient, is only available in specialized transplant centers. Less than
2000 islet cell transplants have been performed between 1999 and 2015 in North America. Islet
transplantation is minimally invasive but still requires the use of immunosuppression. Recent trials have
demonstrated that islet cell transplantation is safe, improves glycemic control, and quality of life99. Most
of the patients will have resolution of hypoglycemic episodes and will improve glucose control with a
secondary goal of achieving insulin independence at least in the short term. Long term insulin
independence remains a challenge after islet cell transplantation100. Future therapies involve the use of
embryonic stem cells or pluripotential stem cells, alternative transplant sites, use of other cell types
besides β-cells in order to facilitate and prolong engraftment, or even gene editing to decrease cell
immunogenicity and eliminate the need for ongoing immunosuppression. In summary, there are both
medical and surgical options for T1DM treatment. These therapeutic options should be tailored to the
unique circumstances of each patient at the specific moment of their disease course. Appropriateness of
surgical and medical options may vary depending on the progression of diabetes during the patient’s
lifespan.
In summary, management of DM after transplantation remains a significant challenge as diagnosis can be
obscured and treatment goals have not been fully delineated. Pharmacological therapies for DM have
expanded significantly over the past few years but their role in improving outcomes in PTDM management
is unknown. PTDM is an underexplored area within the metabolic disorders that affect kidney disease
patients and should be the focus of future research.
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Table 1: Risk factors associated with the development of post-transplant diabetes mellitus
Factors unrelated to transplantation

Older age101
Family history of DM
Ethnicity Black and Hispanic
Central obesity 102,103
Genetic factors104
Sedentary lifestyle

Factors associated with transplantation

Calcineurin inhibitors (tacrolimus >cyclosporine) 20
Glucocorticoids92
Hepatitis C or Cytomegalovirus infection105,106
Post-transplant weight gain
Hypomagnesemia107
Inflammation and relative hypo-adiponectinemia27,28,108
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Table 2. Summary of the studies using SGLT2-i in kidney transplant recipients.
Study reference
Rajasekeran H et al,
201776

Mahling et al, 201977

Shah M et al, 2019 78

AlKindi F et al, 202075

Halden et al, 201979

Schwaiger, E et al,
201980

Song CC et al, 202181

Study design
Case series,
retrospective

Agent
Canagliflozin

Population/Follow up
Key Findings
10 kidney transplant
Patients on canagliflozin
and SPK recipients for had small decrease in
80.5 patient-months
HgA1c, small decrease
in body weight, and a
small decrease in GFR.
Case series,
Empagliflozin
10 kidney transplant
Patients on
retrospective
recipients over 12
empagliflocin had stable
months
GFR, and a small
decrease in HbA1c.
Case series,
Canagliflozin
24 kidney transplant
Patients on canagliflozin
prospective
recipients over 6
had some weight loss,
months
small reduction in BP
and improvement of
HgA1c
Case series,
Empagliflozin and 8 living kidney
Patients on SGLT2-i had
retrospective
dapagliflozin
transplant recipients stable GFR, small
over 3-6 months
decrease in HgA1c, and
small decrease in
weight.
Randomized,
Empagliflozin vs
44 kidney transplant
Empagliflozin use was
prospective,
placebo
recipient over 24
associated with small
double blind
weeks
changes in HbA1c and
weight with no
differences in adverse
events
Prospective study Empagliflozin
14 diabetic kidney
Empagliflozin may be
transplant
used as add-on therapy
participants
for treatment of
diabetes after
transplant.
Retrospective
Empagliflozin,
50 kidney transplant
Patients on SGLT1-i had
study
canagliflozin and participants over 6
decrease weight and
dapagliflozin.
months
increase magnesium
concentration.
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